Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 66 of 98, showing 5 Applications out of 488 total, starting on record 326, ending on 330

# Protocol No Study Title Investigator(s) & Site(s)

326.

ECCT/17/08/07   Tambua Mapema Plus
    Impact of a novel HIV-1 RNA testing intervention to detect acute and prevalent HIV infection and reduce HIV transmission – Tambua Mapema Plus   
Principal Investigator(s)
1. Eduard J Sanders
2. Susan M Graham
Site(s) in Kenya
KEMRI Mtwapa Research Clinic
 
View

327.

ECCT/17/08/06   Enhancing Preventive Therapy of Malaria In children with Sickle cell anemia in East Africa (EPiTOMISE)
    Enhancing Preventive Therapy of Malaria In children with Sickle cell anemia in East Africa (EPiTOMISE)   
Principal Investigator(s)
1. Festus Muigai Njuguna
Site(s) in Kenya
Homa Bay County Hospital
 
View

328.

ECCT/17/08/05   Phase I Safety and Pharmacokinetic Study of Maraviroc in HIV-1-Exposed Infants at Risk of Acquiring HIV-1 Infection.
    Phase I Safety and Pharmacokinetic Study of Maraviroc in HIV-1-Exposed Infants at Risk of Acquiring HIV-1 Infection.   
Principal Investigator(s)
1. Isaac Tsikhutsu
Site(s) in Kenya
Kenya Medical Research Institute/Walter Reed Project HIV Program, Kericho
 
View

329.

ECCT/17/08/04   P1081
    A PHASE IV RANDOMIZED TRIAL TO EVALUATE THE VIROLOGIC RESPONSE AND PHARMACOKINETICS OF TWO DIFFERENT POTENT REGIMENS IN HIV INFECTED WOMEN INITIATING TRIPLE ANTIRETROVIRAL REGIMENS BETWEEN 28 AND 36 WEEKS OF PREGNANCY FOR THE PREVENTION OF MOTHER-TO-CHILD TRANSMISSION:    NICHD P1081   
Principal Investigator(s)
1. FREDRICK KIPYEGON SAWE
Site(s) in Kenya
Kenya Medical Research Institute Walter Reed Project Clinical Research Centre.
 
View

330.

ECCT/17/08/03   Efficacy and safety of KAF156 in combination with LUM-SDF in adults and children with uncomplicated Plasmodium falciparum malaria
    A Phase 2 interventional, multicenter, randomized open-label study to determine the effective and tolerable dose of KAF156 and Lumefantrine Solid Dispersion Formulation in combination, given once daily for 1, 2 and 3-days to adults and children with uncomplicated Plasmodium falciparum malaria.           
Principal Investigator(s)
1. Grace Kiringa Kaguthi
Site(s) in Kenya
KEMRI Siaya
 
View